10-Q: Viking Therapeutics Advances Pipeline, Boosts R&D Spending

Viking Therapeutics reported significantly increased R&D expenses and net losses in Q3 2025, driven by the advancement of its VK2735 programs into Phase 3 and positive Phase 2 oral results, while maintaining a strong cash position.

Summary

• Net loss for the three months ended September 30, 2025, was $90.8 million, compared to $24.9 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $202.0 million, compared to $74.5 million for the same period in 2024.
• Research and development expenses increased by 294.8% to $89.9 million for the three months ended September 30, 2025, and by 171.0% to $191.5 million for the nine months ended September 30, 2025, primarily due to increased clinical study and manufacturing costs.
• General and administrative expenses decreased by 37.5% to $8.6 million for the three months ended September 30, 2025, mainly due to decreased legal and patent services, but increased by 9.1% to $37.1 million for the nine months ended September 30, 2025.
• Cash, cash equivalents, and short-term investments totaled $714.6 million as of September 30, 2025, which is believed to be sufficient to fund operations through at least December 31, 2026.
• The VK2735 subcutaneous formulation entered Phase 3 clinical trials (VANQUISH program) in June 2025 for obesity and type 2 diabetes.
• The VK2735 oral tablet formulation achieved positive top-line results in its Phase 2 clinical trial in August 2025, demonstrating statistically significant weight reductions and good tolerability.
• Multi-year manufacturing agreements were signed with CordenPharma in March 2025 for VK2735 API and finished product supply, securing dedicated capacity for both injectable and oral formulations.
• Positive 52-week histologic data from the VOYAGE Phase 2b study for VK2809 in NASH/MASH were announced in June 2024, showing up to 75% NASH resolution with no worsening of fibrosis.
• The Phase 1b clinical trial of VK0214 for X-ALD showed positive results in October 2024, demonstrating safety, tolerability, and significant reductions in VLCFAs.
• An Investigational New Drug (IND) application for the new Dual Amylin and Calcitonin Receptor Agonist (DACRA) program for obesity is planned for Q4 2025.
• The company is pursuing partnering or licensing opportunities for VK0214 and VK5211.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While financial losses and R&D expenses have significantly increased, this is a direct result of advancing multiple promising drug candidates (VK2735 into Phase 3, positive Phase 2 oral results, VK2809 positive histologic data) and securing critical manufacturing capacity. The strong cash position provides a runway for these advancements. The increased burn is expected for a clinical-stage company with an active pipeline, but the magnitude of the losses is notable. The ongoing legal proceedings and the need for future capital raise introduce elements of uncertainty.

Positives

• Initiation of the VK2735 VANQUISH Phase 3 program for obesity and type 2 diabetes, indicating significant pipeline advancement.
• Positive top-line results from the Phase 2 VENTURE-Oral Dosing trial for VK2735, demonstrating statistically significant weight reductions and a favorable safety profile.
• Strong cash, cash equivalents, and short-term investments totaling $714.6 million as of September 30, 2025, providing liquidity through at least December 31, 2026.
• Secured multi-year manufacturing agreements with CordenPharma for VK2735 API and finished product, including dedicated capacity for 100 million autoinjectors, 100 million vial/syringe products, and over 1 billion oral tablets annually.
• Positive 52-week histologic data for VK2809 in NASH/MASH, showing high rates of NASH resolution (up to 75%) and fibrosis improvement (up to 57%).
• Positive results from the Phase 1b clinical trial of VK0214 for X-ALD, showing safety, tolerability, and significant VLCFA reductions.
• Favorable ruling from the ITC Chief Administrative Law Judge and subsequent affirmation by the full ITC Commission in the trade secret litigation against Ascletis Defendants.

Negatives

• Significant increase in net loss to $90.8 million for the three months and $202.0 million for the nine months ended September 30, 2025, reflecting substantial operational burn.
• Research and development expenses increased by 294.8% and 171.0% for the three and nine months, respectively, indicating a rapid increase in cash burn for clinical trials and manufacturing.
• The company has not generated any revenue since its inception and expects to incur significant losses for the foreseeable future.
• Total current assets decreased from $907.2 million at December 31, 2024, to $738.7 million at September 30, 2025, primarily due to a reduction in short-term investments.
• The company will need to raise additional capital to fund future operations and complete ongoing/planned clinical trials, which may not be available on acceptable terms or could cause dilution.

Risks

• The company is a clinical-stage company with a limited operating history and is expected to incur significant operating losses.
• Substantial dependence on technologies licensed from Ligand Pharmaceuticals Incorporated, with potential harm to business if the Master License Agreement is terminated.
• Dependence on the success of current drug candidates, with no certainty of regulatory approval or commercialization.
• Development of drug candidates may not produce favorable results, hindering commercialization.
• Delays in the commencement or completion of clinical trials could increase costs and delay strategic collaborations.
• Reliance on third parties to conduct preclinical studies and clinical trials, with risks if they fail to meet contractual duties or regulatory requirements.
• Competition from drug candidates approved faster, marketed more effectively, better tolerated, or more effective could reduce or eliminate commercial opportunity.
• Unstable market and economic conditions may have serious adverse consequences on business and financial condition.
• Potential failure to obtain or maintain necessary rights to drug candidates through acquisitions and in-licenses.
• Failure to comply with obligations in intellectual property in-license agreements could lead to loss of rights.
• Drug candidates may cause undesirable side effects, delaying or preventing regulatory approval or commercialization.
• Efforts to discover new drug candidates may not succeed, or candidates recommended for clinical development may not begin clinical trials.
• Limited resources may be expended on specific product candidates or indications, potentially missing more profitable opportunities.
• Need to raise additional capital, which may be unavailable or cause dilution or significant restrictions on operations.
• Subject to a multitude of manufacturing risks, including contamination, equipment failure, and supply disruptions, which could increase costs and limit supply.
• Complete reliance on third parties to manufacture preclinical and clinical drug supplies, with risks of insufficient quantities, unacceptable quality, or high prices.
• Extensive and costly regulation by the FDA, EMA, or comparable foreign authorities, which can cause unanticipated delays or prevent approvals.
• Even if drug candidates receive regulatory approval, they may still face future development and regulatory difficulties, including post-approval studies and restrictions.
• FDA, EMA, and comparable foreign authorities actively enforce laws and regulations prohibiting the promotion of off-label uses.
• Failure to obtain and sustain adequate reimbursement for potential products by third-party payors would materially adversely affect future sales.
• Current and future legislation (e.g., PPACA, IRA) may increase the difficulty and cost of commercializing drug candidates and affect pricing.
• Changes in government funding for regulatory agencies (FDA, SEC) could hinder their ability to perform normal business functions.
• Subject to fraud and abuse and similar laws and regulations, with potential for civil or criminal liabilities.
• Business may be impacted by actions of the current U.S. administration, including executive orders, policies, new legislation, and judicial decisions.
• Compliance with global privacy and data security requirements could result in additional costs and liabilities or inhibit data processing.
• Exposure to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations.
• Governments outside the U.S. tend to impose strict price controls, which may adversely affect revenue.
• Failure to retain current senior management and scientific personnel, or attract additional key personnel, could hinder drug development.
• Need to increase the size of the organization and successfully manage growth.
• Exposure to product liability, non-clinical, and clinical liability risks.
• Research and development activities involve hazardous materials, subjecting the company to regulation, costs, and potential liabilities.
• Reliance on information technology, with risks of failure, inadequacy, interruption, or security lapses, including cybersecurity incidents.
• Artificial intelligence presents risks and challenges, including security risks to confidential information and potential reputational harm or liability.
• Business disruptions such as natural disasters or geopolitical conflicts could seriously harm future revenues and financial condition.
• Strategic transactions (acquisitions, in-licensing) could impact liquidity, increase expenses, and distract management.
• Employment agreements with officers and certain employees may require severance benefits in connection with a change in control.
• Ability to effectively monitor and respond to evolving sustainability (ESG) matters may impose unexpected costs or reputational harm.
• The market price of common stock may be highly volatile.
• An active trading market for common stock may not be sustained.
• Management owns a significant percentage of stock, exerting significant control over stockholder approval matters.
• Internal control over financial reporting may not meet Sarbanes-Oxley Act standards.
• Operating as a public company incurs increased costs and requires substantial management time for compliance.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, stock price and trading volume could decline.
• Sales of a substantial number of shares by existing stockholders or future issuances could cause stock price to fall.
• Management has broad discretion over the use of proceeds from financings and available cash.
• Risk of securities class action litigation.
• Ability to use net operating loss carryforwards may be subject to limitations under Section 382 of the Internal Revenue Code.
• Changes in tax laws could adversely affect business and financial condition.
• No dividends on common stock are expected, limiting returns to stock appreciation.
• Provisions in charter documents and Delaware law could make it more difficult or expensive for a third party to acquire the company.
• Bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain actions.
• Timing and amount of any repurchases under the stock repurchase program are subject to uncertainties.

Future Outlook

The company anticipates continued losses for the foreseeable future, with losses expected to increase materially as drug development activities expand, regulatory approvals are sought, and commercialization efforts begin. Additional capital will be required to fund operations and complete ongoing and planned clinical trials, with future financing expected through public or private equity or debt offerings. The company plans to file an IND for its DACRA program in Q4 2025 and intends to pursue partnering or licensing opportunities for VK0214 and VK5211. The current cash, cash equivalents, and short-term investments are projected to fund operations through at least December 31, 2026.

Management Comments

• Management believes the current cash, cash equivalents, and short-term investments will be sufficient to fund operations through at least December 31, 2026.
• Management expects to incur increased research and development expenses in the future as efforts continue towards advancing the VK2735, VK2809, and VK0214 programs and additional programs.
• Management expects general and administrative expenses to continue to increase in the future to support increased research and development activities and costs associated with being a public company.
• Management plans to continue to vigorously pursue all legal remedies in the ongoing trade secret litigation against Ascletis Defendants.

Industry Context

The biopharmaceutical industry is characterized by intense competition and rapidly advancing technologies. Viking Therapeutics operates in highly competitive segments, particularly obesity and NASH/MASH. For obesity, its VK2735 program faces established competitors like Novo Nordisk A/S (Semaglutide/Wegovy, liraglutide/Saxenda) and Eli Lilly and Company (tirzepatide/Zepbound), as well as numerous late-stage development programs. In NASH/MASH, VK2809 competes with Madrigal Pharmaceuticals' Resmetirom (Rezdiffra), the only approved therapy in the U.S., and a crowded pipeline of experimental therapies from companies like Galmed, Inventiva, Gilead, Pfizer, Akero Therapeutics, and 89bio. The X-ALD market, where VK0214 is positioned, currently lacks approved treatments, but gene therapies and experimental therapies from companies like Minoryx Therapeutics and bluebird bio Inc. represent emerging competition. The significant R&D investment by Viking reflects the high capital requirements and competitive pressures within these therapeutic areas.

Comparison to Industry Standards

• For obesity, VK2735's Phase 2 subcutaneous results (up to 14.7% weight reduction at 13 weeks) and oral results (up to 5.3% at 28 days) are competitive with existing GLP-1/GIP agonists like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which have demonstrated significant weight loss over longer durations. The initiation of Phase 3 for VK2735 positions it against these market leaders and other late-stage candidates such as CagriSema (Novo Nordisk), orforglipron and retatrutide (Eli Lilly), and survodutide (Boehringer Ingelheim).
• For NASH/MASH, VK2809's Phase 2b histologic data (up to 75% NASH resolution, up to 57% 1-stage fibrosis improvement) compares favorably to Madrigal Pharmaceuticals' Rezdiffra, the first FDA-approved therapy, and other pipeline candidates like lanifibranor (Inventiva S.A.) and efruxifermin (Akero Therapeutics, Inc.), indicating strong efficacy signals in a challenging disease area.
• For X-ALD, VK0214's Phase 1b data showing significant VLCFA reductions is promising given the lack of approved treatments for the adrenomyeloneurophathy (AMN) form. While gene therapies like elivaldogene autotemcel (bluebird bio, Inc.) exist for cerebral X-ALD, VK0214 targets a different patient population and offers a non-invasive approach, potentially differentiating it from competitors like Minoryx Therapeutics S.L. and Spur Therapeutics, Inc.

Corporate Governance

Legal Proceedings

• Ongoing trade secret litigation against Ascletis Bioscience Co., Ltd. and affiliates in the Southern District of California, San Diego division, alleging violations of the Defend Trade Secrets Act, California Uniform Trade Secrets Act, breach of contract, breach of implied covenant of good faith and fair dealing, and tortious interference with contract.
• Related action filed against Ascletis Defendants in the International Trade Commission (ITC) for unlawful and unfair methods of competition, arising from misappropriation of trade secrets.
• On October 3, 2024, the ITC's Chief Administrative Law Judge determined in favor of Viking, finding misappropriation of trade secrets and discovery misconduct by Ascletis Defendants, warranting monetary and non-monetary sanctions.
• On May 29, 2025, the full ITC Commission affirmed the substantial majority of the Chief Administrative Law Judge's determinations in Viking's favor.
• On September 26, 2025, Ascletis Defendants filed a notice of appeal in the United States Court of Appeals for the Federal Circuit, challenging the ITC Commission's affirmance.
• On September 26, 2025, Viking also filed a notice of appeal in the United States Court of Appeals for the Federal Circuit, challenging a narrow portion of the ITC Commission's decision.

Related Party Transactions

• The company's business is substantially dependent on technology licensed from Ligand Pharmaceuticals Incorporated (Ligand) through a Master License Agreement, granting exclusive worldwide rights to VK2809, VK0214, VK5211, VK0612, and preclinical programs. The company may be obligated to pay Ligand up to approximately $1.54 billion in development, regulatory, and sales milestones, plus single-digit royalties on future worldwide net product sales.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises, stock price volatility due to clinical trial results and market conditions, and potential long-term value creation from pipeline advancement. The stock repurchase program offers a potential mechanism for shareholder return.
• Employees: Increased stock-based compensation expenses and the replacement of equity incentive plans (2014 Plan/ESPP by 2024 Plan/ESPP) impact employee compensation and retention. Growth in R&D activities suggests increased hiring and opportunities.
• Patients: Advancement of VK2735 into Phase 3 and positive Phase 2 oral results, along with progress in VK2809 and VK0214, offers hope for novel therapies for metabolic and endocrine disorders like obesity, NASH/MASH, and X-ALD.
• Suppliers/Partners: New multi-year manufacturing agreements with CordenPharma for VK2735 ensure dedicated capacity and provide business for the supplier, while securing critical supply for the company's pipeline.
• Creditors: The company's strong cash position and access to capital markets (shelf registration, ATM offering) mitigate immediate credit risk, but increasing losses indicate reliance on external funding.

Next Steps

• Continue the VANQUISH Phase 3 program for VK2735 (subcutaneous formulation) in adults with obesity and obese/overweight adults with type 2 diabetes.
• Advance the VK2735 oral tablet formulation following positive Phase 2 results.
• File an Investigational New Drug (IND) application for the Dual Amylin and Calcitonin Receptor Agonist (DACRA) program in the fourth quarter of 2025.
• Pursue partnering or licensing opportunities for VK0214 (for X-ALD) and VK5211 (for hip fracture recovery).
• Continue to vigorously pursue legal remedies in the trade secret litigation against Ascletis Defendants, including appeals.
• Transition corporate headquarters to a larger new premises (9920 Pacific Heights Blvd, Suite 500) upon substantial completion of tenant improvements or April 1, 2026.

Key Dates

Recommendation

Viking Therapeutics is in a critical growth phase, marked by significant advancements in its pipeline, particularly the VK2735 program entering Phase 3 and showing positive Phase 2 oral results. This clinical progress, coupled with strategic manufacturing agreements and a strong cash balance of $714.6 million, provides a solid foundation for future development. However, the company is experiencing a substantial increase in R&D expenses and net losses, reflecting the high cost of late-stage clinical trials and drug development. While the cash runway is projected through late 2026, the explicit need for future capital raises introduces potential dilution risk. The competitive landscape in obesity and NASH/MASH is intense, and while Viking's candidates show promise, commercial success is not guaranteed. The ongoing trade secret litigation adds a layer of legal uncertainty. Given the significant R&D burn and the need for future financing, balanced against the promising clinical data and pipeline progression, a 'hold' recommendation is appropriate for investors who are comfortable with the inherent risks of a clinical-stage biopharmaceutical company but want to monitor the execution of its ambitious development plans and capital management.

Keywords

Biopharmaceutical, Metabolic Disorders, Endocrine Disorders, Obesity, NASH, MASH, X-ALD, GLP-1, GIP, TR beta, VK2735, VK2809, VK0214, Clinical Trials, Drug Development, SEC Filing, 10-Q, CordenPharma, Manufacturing, VANQUISH, VENTURE, VOYAGE, DACRA